三元生物
(301206)
| 流通市值：30.79亿 | | | 总市值：57.89亿 |
| 流通股本：1.08亿 | | | 总股本：2.02亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,635,903,927.35 | 160,292,353.03 | 86,800,655.34 | 76,792,909.06 |
| 应收票据及应收账款 | 104,472,885.32 | 122,365,190.07 | 79,531,046.42 | 83,188,224.95 |
| 其中：应收票据 | 1,708,500 | 3,500,650 | 5,618,307 | 3,431,957 |
| 应收账款 | 102,764,385.32 | 118,864,540.07 | 73,912,739.42 | 79,756,267.95 |
| 预付款项 | 5,591,619.72 | 9,003,103.23 | 12,474,024.63 | 8,162,224.61 |
| 其他应收款合计 | 1,938,425.28 | 8,709,783.08 | 4,263,214.61 | 4,297,905.75 |
| 存货 | 158,835,695.87 | 142,707,159.57 | 118,786,624.02 | 148,244,242.15 |
| 一年内到期的非流动资产 | 358,995,916.67 | 2,938,873,041.66 | 2,916,095,465.9 | - |
| 其他流动资产 | 7,905,951.69 | 6,047,355.94 | 8,253,136.38 | 14,448,276.1 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,933,444,421.9 | 3,387,997,986.58 | 3,356,204,167.3 | 335,133,782.62 |
| 非流动资产: | | | | |
| 长期股权投资 | 52,696,100.35 | 53,177,334.33 | 55,764,683.08 | 55,818,437.13 |
| 固定资产 | 983,509,747.22 | 998,677,280.29 | 989,234,419.37 | 866,742,308.95 |
| 在建工程 | 69,802,945.11 | 48,648,309.47 | 47,839,909.23 | 154,983,218.34 |
| 无形资产 | 46,152,820.08 | 46,425,715.71 | 46,712,598.83 | 47,000,575.46 |
| 其他非流动资产 | 665,915,594.62 | 270,325,112.74 | 268,077,946.42 | 3,387,723,146.45 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,818,077,207.38 | 1,417,253,752.54 | 1,407,629,556.93 | 4,512,267,686.33 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,751,521,629.28 | 4,805,251,739.12 | 4,763,833,724.23 | 4,847,401,468.95 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 170,756,710.15 | 175,698,475.75 | 168,724,477.68 | 244,886,712.96 |
| 其中：应付票据 | 111,697,672.5 | 91,294,600 | 111,286,205.74 | 192,231,998.44 |
| 应付账款 | 59,059,037.65 | 84,403,875.75 | 57,438,271.94 | 52,654,714.52 |
| 合同负债 | 6,019,650.71 | 4,815,825.98 | 5,337,921.22 | 4,289,650.9 |
| 应付职工薪酬 | 5,293,906.37 | 7,821,271.78 | 5,929,062.19 | 5,264,263.54 |
| 应交税费 | 13,497,628.92 | 1,078,479.47 | 2,481,703.14 | 1,122,057.15 |
| 其他应付款合计 | 1,471,904.3 | 50,650,376.56 | 69,488.6 | 85,634 |
| 应付股利 | - | 50,407,500 | - | - |
| 其他流动负债 | 1,093,530.75 | 3,603,041.74 | 4,940,330 | 3,622,354.08 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 198,133,331.2 | 243,667,471.28 | 187,482,982.83 | 259,270,672.63 |
| 非流动负债: | | | | |
| 递延收益 | 3,236,621.92 | 3,508,977.46 | 3,838,210.8 | 4,089,755.25 |
| 递延所得税负债 | 57,529,016.82 | 66,867,090.56 | 48,350,281.47 | 47,578,733.52 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 60,765,638.74 | 70,376,068.02 | 52,188,492.27 | 51,668,488.77 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 258,898,969.94 | 314,043,539.3 | 239,671,475.1 | 310,939,161.4 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 202,325,700 | 202,325,700 | 202,325,700 | 202,325,700 |
| 资本公积 | 3,517,613,730.51 | 3,517,613,730.51 | 3,517,613,730.51 | 3,517,613,730.51 |
| 减:库存股 | 41,481,669.36 | 17,604,440.2 | 11,113,724.66 | - |
| 盈余公积 | 83,226,182.31 | 83,226,182.31 | 80,843,126.8 | 77,926,858.36 |
| 未分配利润 | 730,561,013.9 | 705,647,027.2 | 734,493,416.48 | 738,596,018.68 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 4,492,244,957.36 | 4,491,208,199.82 | 4,524,162,249.13 | 4,536,462,307.55 |
| 少数股东权益 | 377,701.98 | - | - | - |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,492,622,659.34 | 4,491,208,199.82 | 4,524,162,249.13 | 4,536,462,307.55 |
| 负债和股东权益合计 | 4,751,521,629.28 | 4,805,251,739.12 | 4,763,833,724.23 | 4,847,401,468.95 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |